Endo News
September 16, 2008:
DONE! My 37-year-old daughter has Addison's disease.
From http://www.kilgorenewsherald.com/news/2008/0916/advice/009.html
DEAR DR. DONOHUE: My 37-year-old daughter has Addison's disease. Many doctors saw her when she was hospitalized a year ago. She had to go back to the hospital because of stomach upset, back pain and dehydration. Her skin has darkened. She was told she would be fine after she started steroids. This hasn't happened. She is constantly sick. Do you have any good news? -- L.K.
ANSWER: With Addison's disease, the adrenal glands have stopped producing their many hormones. Those hormones include cortisone and aldosterone. Cortisone gives us energy, combats inflammation and figures into many of the body's most important functions. Aldosterone is essential for blood pressure maintenance. Without adrenal gland hormones, the skin darkens, especially the elbow skin and the creases in the hands.
Treatment is straightforward: Replace the missing hormones. Maybe the dosage of her hormone medicines needs revision. If she's hasn't shortly turned the corner, she should get a second opinion from an endocrinologist, a specialist in this kind of illness.Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss
Thomas Reinehr* and Christian L. Roth
Vestische Hospital for Children and Adolescents Datteln, University of Witten/Herdecke, Germany; Seattle Children's Hospital Research Institute, University of Washington, USA
* To whom correspondence should be addressed. E-mail: T.Reinehr@kinderklinik-datteln.de.
Context: There are very limited data available concerning the relationships between fetuin-A, weight status, non-alcoholic fatty liver disease (NAFLD), and features of the metabolic syndrome (MetS) in obese humans and especially in children.
Objective: To study the longitudinal relationships between fetuin-A, NAFLD, and MetS in obese children.
Design: One-year longitudinal follow-up study.
Setting: Primary care.
Patients: Thirty-six obese and 14 lean children.
Intervention: Outpatient one-year intervention program based on exercise, behavior and nutrition therapy.
Main Outcomes Measures: Changes of weight status (SDS-BMI), waist circumference, fetuin-A, blood pressure, lipids, transaminases, insulin resistance index HOMA, and prevalence of NAFLD (defined by liver ultrasound).
Results: The 12 obese children with NAFLD had significantly higher fetuin-A levels (0.35±0.07g/l) than the 24 obese children without NAFLD (0.29±0.06g/l) and the 14 normal weight children (0.29±0.05g/l). Fetuin-A levels were independent of age, pubertal stage, and gender. Fetuin-A correlated significantly to systolic (r=0.50) and diastolic blood pressure (r=0.41), insulin resistance index HOMA (r=0.28), and HDL-cholesterol (r=-0.31). Changes of fetuin-A correlated significantly to changes of insulin resistance index HOMA (r=0.34), systolic (r=0.31) and diastolic blood pressure (r=0.37), and waist circumferences (r=0.36). Substantial weight loss in 21 children led to a significant decrease of fetuin-A and the prevalence of NAFLD in contrast to the 15 children without substantial weight loss.
Conclusion: Fetuin-A levels were higher in children with NAFLD and were related to insulin resistance and to features of the MetS in both cross-sectional and longitudinal analyses. Therefore, fetuin-A might be a new promising link between obesity and its comorbidities.
Key words: fetuin-A • insulin • triglycerides • obesity • children • weight loss • insulin resistance • metabolic syndrome • blood pressure • HDL- cholesterol • non alcoholic-fatty liver disease
Insulin glargine in the treatment of type 1 and type 2 diabetes 59
Anthony H Barnett
Birmingham Heartlands Hospital, Birmingham, West Midlands, England, UK
Abstract: Insulin glargine is an analogue of human insulin that is modified to provide a consistent level of plasma insulin over a long duration. Pharmacokinetic and pharmacodynamic studies show that a single injection of insulin glargine leads to a smooth 24-hour time–action profile with no undesirable pronounced peaks of activity. In clinical trials, this profile has been associated with at least equivalent, if not better, glycemic control than other traditional basal insulins and a significantly lower rate of overall and nocturnal hypoglycemia. The convenience of a once-daily injection, a lack of need for resuspension (insulin glargine is a clear solution when injected), and lower rates of hypoglycemia should translate into improvements in patient treatment satisfaction. This review appraises the evidence for the view that insulin glargine represents an advance in basal insulin therapy for both type 1 and type 2 diabetes patients.
Keywords: Insulin glargine, basal insulin therapy, diabetes, review
September 15, 2008:
Modern techniques for pituitary radiotherapy
Reviews in Endocrine and Metabolic Disease
Earlier News Items at http://www.cushings-help.com/endo_news.htm
Labels: news